Artículo

Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice

Fiore, Esteban Juan Icon; Bayo Fina, Juan Miguel Icon; García, Mariana Gabriela Icon; Malvicini, Mariana Icon; Lloyd, Rodrigo ; Piccioni, Flavia Valeria Icon; Rizzo, Manglio Miguel Icon; Peixoto, Estanislao Icon; Sola, M. Beatriz ; Atorrasagasti, María Catalina Icon; Alaniz, Laura Daniela Icon; Camilletti, María Andrea Icon; Enguita, Mónica ; Prieto, Jesús ; Aquino, Jorge Benjamin Icon; Mazzolini Rizzo, Guillermo Daniel Icon

Otros responsables

Fecha

12/2014

Editorial

Mary Ann Liebert

Revista

Stem Cells And Development

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

1547-3287

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Resumen

Liver cirrhosis involves chronic wound healing and fibrotic processes. Mesenchymal stromal cells (MSCs) are multipotent adult progenitor cells that are used as vehicles of therapeutic genes. Insulin growth factor like-I (IGF-I) was shown to counteract liver fibrosis. We aimed at analyzing the effect of applying IGF-I overexpressing mouse bone marrow-derived MSCs on hepatic fibrosis. Fibrosis was induced by chronic thioacetamide application or bile duct ligation. MSCs engineered to produce green fluorescent protein (GFP) (AdGFP-MSCs) or IGF-I (AdIGF-I-MSCs) were applied systemically, and changes in collagen deposition and in the expression of key pro-fibrogenic and pro-regenerative genes/proteins were assessed. In addition, immunogenicity of transduced cells was analyzed. Liver fibrosis was further ameliorated after a single-dose application of AdIGF-I-MSCs when compared with AdGFP-MSCs and/or recombinant IGF-I treatments. Interestingly, an early and transitory upregulation in IGF-I and hepatocyte growth factor (HGF) mRNA expression was found in the liver of MSC-treated animals, which was more pronounced in AdIGF-I-MSCs condition. A reduction in hepatic stellate cell activation status was found after incubation with MSCs conditioned media. In addition, the AdIGF-I-MSCs cell-free supernatant induced the expression of IGF-I and HGF in primary cultured hepatocytes. From day 1 after transplantation, the proliferation marker proliferating cell nuclear antigen was upregulated in the liver of AdIGF-I-MSCs group, mainly in hepatocytes. MSCs were in vivo traced till day 14 after injection. In addition, multiple doses of Ad-IGF-I-MSCs likely suppressed antiviral immune response and it further reduced collagen deposition. Our results uncover early events that are likely involved in the anti-fibrogenic effect of genetically modified MSCs and overall would support the use of AdIGF-I-MSCs in treatment of liver fibrosis.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa